NASDAQ:ACRX - AcelRx Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.90 +0.27 (+10.27 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$2.90
Today's Range$2.72 - $2.99
52-Week Range$1.65 - $5.05
Volume7.48 million shs
Average Volume1.62 million shs
Market Capitalization$179.53 million
P/E Ratio-2.64
Dividend YieldN/A
Beta1.99
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRX
CUSIPN/A
Phone650-216-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.99 million
Book Value($0.73) per share

Profitability

Net Income$-51,500,000.00
Net Margins-1,952.41%

Miscellaneous

Employees41
Market Cap$179.53 million
OptionableOptionable

AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced its quarterly earnings results on Monday, November, 5th. The specialty pharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.01. The specialty pharmaceutical company earned $0.38 million during the quarter, compared to the consensus estimate of $1.10 million. View AcelRx Pharmaceuticals' Earnings History.

When is AcelRx Pharmaceuticals' next earnings date?

AcelRx Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for AcelRx Pharmaceuticals.

What price target have analysts set for ACRX?

8 analysts have issued 1-year target prices for AcelRx Pharmaceuticals' shares. Their predictions range from $7.00 to $10.00. On average, they anticipate AcelRx Pharmaceuticals' share price to reach $8.4286 in the next year. This suggests a possible upside of 190.6% from the stock's current price. View Analyst Price Targets for AcelRx Pharmaceuticals.

What is the consensus analysts' recommendation for AcelRx Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AcelRx Pharmaceuticals.

What are Wall Street analysts saying about AcelRx Pharmaceuticals stock?

Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (1/8/2019)
  • 2. Cantor Fitzgerald analysts commented, ". Post ACRX’s analyst day in NYC, we reiterate our Overweight rating and 12-month price target of $9. Despite Dsuvia approval on the large market opportunity ahead for the pain product, we believe the market continues to undervalue ACRX stock. The KOL’s in attendance today were very positive on their willingness to use Dsuvia in their respective emergency rooms and/or surgery centers, underscoring our positive thesis for Dsuvia’s prospects." (12/11/2018)
  • 3. HC Wainwright analysts commented, "916-3963, Probability of approval Risk-adj value Full value Dsuvia – U.S. 100% $8.06 $8.06 Shares outstanding 61,907 Zalviso – EU 100% $0.15 $0.15 Current share price $4.27 Discount rate 12.5% Zalviso – U.S." (11/6/2018)

Has AcelRx Pharmaceuticals been receiving favorable news coverage?

News headlines about ACRX stock have been trending somewhat negative this week, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AcelRx Pharmaceuticals earned a news impact score of -1.0 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.

Are investors shorting AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 11,374,712 shares, an increase of 14.8% from the January 15th total of 9,904,730 shares. Based on an average daily trading volume, of 1,584,320 shares, the short-interest ratio is presently 7.2 days. Currently, 16.8% of the company's shares are short sold. View AcelRx Pharmaceuticals' Current Options Chain.

Who are some of AcelRx Pharmaceuticals' key competitors?

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the folowing people:
  • Mr. Vincent J. Angotti, CEO & Director (Age 51)
  • Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 56)
  • Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 50)
  • Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 67)
  • Mr. Anil N. Dasu, Chief Engineering Officer (Age 56)

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.77%), Monashee Investment Management LLC (2.67%), Two Sigma Investments LP (0.90%), Geode Capital Management LLC (0.77%), Barclays PLC (0.56%) and Fosun International Ltd (0.49%). Company insiders that own AcelRx Pharmaceuticals stock include Badri N Dasu, Lawrence G Hamel, Life Sciences Maste Perceptive, Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Institutional Ownership Trends for AcelRx Pharmaceuticals.

Which institutional investors are selling AcelRx Pharmaceuticals stock?

ACRX stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, D. E. Shaw & Co. Inc., D.A. Davidson & CO. and Cornerstone Capital Inc.. Company insiders that have sold AcelRx Pharmaceuticals company stock in the last year include Badri N Dasu and Lawrence G Hamel. View Insider Buying and Selling for AcelRx Pharmaceuticals.

Which institutional investors are buying AcelRx Pharmaceuticals stock?

ACRX stock was purchased by a variety of institutional investors in the last quarter, including Monashee Investment Management LLC, BlackRock Inc., Two Sigma Investments LP, Barclays PLC, Geode Capital Management LLC, Millennium Management LLC, Two Sigma Advisers LP and Bank of New York Mellon Corp. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Insider Buying and Selling for AcelRx Pharmaceuticals.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $2.90.

How big of a company is AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals has a market capitalization of $179.53 million and generates $7.99 million in revenue each year. The specialty pharmaceutical company earns $-51,500,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. AcelRx Pharmaceuticals employs 41 workers across the globe.

What is AcelRx Pharmaceuticals' official website?

The official website for AcelRx Pharmaceuticals is http://www.acelrx.com.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]


MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  372 (Vote Outperform)
Underperform Votes:  299 (Vote Underperform)
Total Votes:  671
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel